Intra-Cellular Therapies (NASDAQ:ITCI) Releases Earnings Results, Misses Estimates By $0.07 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Briefing.com reports. The business had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The firm’s revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.25) earnings per share.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI traded up $0.69 during midday trading on Thursday, reaching $86.16. 446,622 shares of the company traded hands, compared to its average volume of 868,354. The stock’s 50-day simple moving average is $74.73 and its 200-day simple moving average is $73.04. Intra-Cellular Therapies has a 12 month low of $46.10 and a 12 month high of $88.00. The firm has a market cap of $9.10 billion, a PE ratio of -73.68 and a beta of 1.00.

Insider Buying and Selling

In other news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 28,680 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $79,696,697.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 175,316 shares of company stock worth $13,037,345 in the last quarter. 3.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ITCI shares. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Royal Bank of Canada increased their price target on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $96.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.